The increased potency of dasatinib, combined with its ability to bind multiple conformation of BCR-ABL, produces significant efficacy in patients with CML and Ph+ ALL. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.